Real-World Outcomes After Switching to Immune Globulin Subcutaneous 16.5% In Patients with Primary Humoral Immunodeficiency: A 3-Year Study

Presented at AAAAI 2023

Authors:
Jeffrey W. Langford, MD, AE-C
Richard F. Herrscher, MD, FACAAI
Dawn N. Kim-Romo, PharmD, PhD, MS
Lucinda J. Van Anglen, PharmD